Paper published in “Biochimica et Biophysica Acta” describes how MUC1-C is involved in driving a program that integrates the induction of EMT with activation of stem cell traits, epigenetic reprogramming and immune evasion in human carcinomas.

The MUC1-C-integrated program provides support for the importance of this oncoprotein in cancer progression and emphasizes a critical need for developing agents against this widely overexpressed target in human malignancies.

DETAILS